How Enveda Biotherapeutics announced its $311M Series E on X
Life is smart. Let’s learn from it.
What Enveda Biotherapeutics launched

Today we are announcing a $311M Series E to bring pharma into the 21st century. Enveda started with a thesis: a molecule that evolution has already refined is a better place to begin than one designed from scratch. This year, two first-in-class molecules discovered by Enveda https://t.co/AoAkrRI9Ce
Transcript
How LaunchVideo.com rated the launch
LaunchVideo.com rating
About the launch
Enveda Biotherapeutics is a Boulder, Colorado biotech using artificial intelligence to identify molecules in living organisms like plants and microbes, predict their structure and function, and rank them by drug potential before its chemists turn the most promising into drug candidates. The premise, as the launch tweet frames it, is that molecules evolution has already refined are a better starting point than ones designed from scratch, and the company is now announcing a $311M Series E to push that thesis deeper into the clinic. The round was led by Catalio Capital Management and includes 16 other backers, among them Surveyor Capital, T. Rowe Price, Lux Capital and a sovereign wealth fund, on top of more than $530 million in prior venture backing including a $150 million Series D earlier in 2025. The timing follows real clinical readouts rather than just platform claims. Enveda revealed Phase 1 data this year from a pair of AI-designed programs for atopic dermatitis and obesity, one of which, ENV-294, is a molecular glue that showed potential to reduce eczema symptoms in a small, early clinical trial. The company was founded in 2019 by Viswa Colluru, who has said Enveda is already evaluating 17 programs to emerge from its research, arguing that first-in-class mechanisms are what move the needle for patients and drive returns . For founders, investors, and operators tracking AI-native drug discovery, this launch is a useful data point on what happens when a natural-products platform actually produces clinical assets, and how much capital the market is willing to put behind that shift.
Tags
Questions
Frequently asked questions
The Enveda Biotherapeutics launch post reached 31K views on X, with 130 likes, 21 reposts, 14 comments, 31 bookmarks.
Enveda Biotherapeutics launched on X on September 23, 2026 with the message "Life is smart. Let’s learn from it.".
Enveda Biotherapeutics is a Boulder, Colorado biotech using artificial intelligence to identify molecules in living organisms like plants and microbes, predict their structure and function, and rank.
LaunchVideo.com rated the Enveda Biotherapeutics launch 2.60 out of 5: hook 3/5, editing / creativity 2/5, copy 3/5, sentiment of launch 3/5, distribution strategy 2/5.







